| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 85-88 |
| Number of pages | 4 |
| Journal | Cancer Chemotherapy & Pharmacology |
| Volume | 45 |
| Publication status | Published - 2000 |
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early clinical study group (ECSG)
S Aamdal, B Lund, I Koier, M Houten, J Wanders, Jaap Verweij
Research output: Contribution to journal › Article › Academic › peer-review
13
Citations
(Scopus)